GO:0006003 fructose 2,6-bisphosphate metabolic process: Glycolytic Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006003 describes the chemical reactions and pathways involving fructose 2,6-bisphosphate, a key regulator of glycolysis and gluconeogenesis.
• Fructose 2,6-bisphosphate activates phosphofructokinase and inhibits fructose 1,6-bisphosphatase, thereby controlling carbon flux between glycolysis and gluconeogenesis.
• The bifunctional enzyme PFKFB (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) synthesizes and degrades fructose 2,6-bisphosphate in response to hormonal and metabolic signals.
• Fructose 2,6-bisphosphate metabolism is conserved across eukaryotes and is a point of control for growth factors, oncogenes, and tumor promoters.
• Dysregulation of fructose 2,6-bisphosphate levels is implicated in cancer, diabetes, and cardiac ischemia, making it a target for metabolic research.
• CRISPR-based knockout, knock-in, and overexpression models of PFKFB genes enable precise dissection of fructose 2,6-bisphosphate metabolic process in disease contexts.
Description
Fructose 2,6-bisphosphate metabolic process (GO:0006003) encompasses the chemical reactions and pathways involving fructose 2,6-bisphosphate, a potent allosteric regulator of glycolysis and gluconeogenesis. This metabolite is not a glycolytic intermediate but a signal that coordinates carbohydrate metabolism in response to hormonal and nutritional cues. Since its discovery, fructose 2,6-bisphosphate has been recognized as a central node in the control of hepatic glucose production and peripheral glucose utilization. Researchers study this process to understand how cells switch between energy storage and energy production, and how this switch goes awry in metabolic diseases and cancer. The pathway is defined by the opposing activities of bifunctional enzymes that synthesize and degrade fructose 2,6-bisphosphate, making it a paradigm for metabolic regulation.
fructose 2,6-bisphosphate metabolic process At A Glance
| GO ID | GO:0006003 |
|---|---|
| GO term | fructose 2,6-bisphosphate metabolic process |
| Ontology | biological_process |
| Synonym | fructose 2,6-bisphosphate metabolism |
| Major function | Regulation of glycolysis and gluconeogenesis via allosteric control of phosphofructokinase and fructose 1,6-bisphosphatase |
| Key enzymes | PFKFB1, PFKFB2, PFKFB3, PFKFB4 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) |
| Substrate | Fructose 6-phosphate and ATP (synthesis); fructose 2,6-bisphosphate (degradation) |
| Regulatory role | Activates phosphofructokinase; inhibits fructose 1,6-bisphosphatase |
| Evolutionary conservation | Present in eukaryotes and some bacteria; conserved regulatory mechanism |
What Is GO:0006003?
GO:0006003, fructose 2,6-bisphosphate metabolic process, is defined as the chemical reactions and pathways involving fructose 2,6-bisphosphate. The D enantiomer is an important regulator of the glycolytic and gluconeogenic pathways. It inhibits fructose 1,6-bisphosphatase and activates phosphofructokinase. This process includes the synthesis of fructose 2,6-bisphosphate from fructose 6-phosphate and ATP, and its degradation to fructose 6-phosphate and inorganic phosphate, catalyzed by bifunctional enzymes.
Why Is fructose 2,6-bisphosphate metabolic process Important in Cell Biology?
Fructose 2,6-bisphosphate metabolic process is critically important because it determines the balance between glycolysis and gluconeogenesis, two opposing pathways that must be tightly regulated to maintain blood glucose homeostasis. In the liver, this process is the primary target of glucagon and insulin signaling, allowing rapid adaptation to fasting and feeding states. In cancer cells, elevated fructose 2,6-bisphosphate levels support the Warburg effect by promoting glycolysis even under aerobic conditions. In the heart, fructose 2,6-bisphosphate is essential for matching glycolytic flux to cardiac workload. Thus, understanding this process provides insights into diabetes, cancer, and heart disease, and offers opportunities for therapeutic intervention.
• Controls the rate-limiting step of glycolysis by activating phosphofructokinase-1.
• Inhibits fructose 1,6-bisphosphatase, thereby suppressing gluconeogenesis.
• Mediates hormonal regulation of hepatic glucose metabolism by glucagon and insulin.
• Supports the Warburg effect in cancer cells by maintaining high glycolytic flux.
• Essential for cardiac glycolysis and contractile function under stress.
• Conserved across eukaryotes, providing a model for metabolic regulation.
• Dysregulated in type 2 diabetes and obesity, contributing to hyperglycemia.
• Target for small-molecule modulators of PFKFB enzymes in oncology.
• Plays a role in growth factor and oncogene signaling pathways.
• Provides a biochemical switch for cellular energy homeostasis.
What Happens During fructose 2,6-bisphosphate metabolic process?
Synthesis of fructose 2,6-bisphosphate
In simple terms: The cell makes fructose 2,6-bisphosphate by adding a phosphate group to fructose 6-phosphate.
Fructose 2,6-bisphosphate is synthesized from fructose 6-phosphate and ATP by the kinase domain of bifunctional PFKFB enzymes. This reaction is catalyzed by 6-phosphofructo-2-kinase, which transfers a phosphate from ATP to the C2 position of fructose 6-phosphate. The synthesis is stimulated by fructose 6-phosphate and inhibited by citrate and low pH. In the liver, the kinase activity is promoted by insulin signaling, leading to increased fructose 2,6-bisphosphate levels during feeding.
Degradation of fructose 2,6-bisphosphate
In simple terms: The cell breaks down fructose 2,6-bisphosphate to fructose 6-phosphate and phosphate.
The degradation of fructose 2,6-bisphosphate is catalyzed by the phosphatase domain of PFKFB enzymes, which hydrolyzes the C2 phosphate to yield fructose 6-phosphate and inorganic phosphate. This activity is stimulated by glucagon and cAMP-dependent phosphorylation in the liver, reducing fructose 2,6-bisphosphate levels during fasting. The balance between kinase and phosphatase activities determines the steady-state concentration of fructose 2,6-bisphosphate.
Allosteric regulation of phosphofructokinase-1
In simple terms: Fructose 2,6-bisphosphate turns on the enzyme that commits glucose to glycolysis.
Fructose 2,6-bisphosphate activates phosphofructokinase-1 (PFK-1) by increasing its affinity for fructose 6-phosphate and relieving inhibition by ATP and citrate. This activation promotes glycolytic flux and is a key mechanism for stimulating glucose utilization in response to increased energy demand. In cancer cells, elevated fructose 2,6-bisphosphate maintains PFK-1 activity, supporting aerobic glycolysis.
Inhibition of fructose 1,6-bisphosphatase
In simple terms: Fructose 2,6-bisphosphate blocks the enzyme that makes glucose from non-carbohydrate sources.
Fructose 2,6-bisphosphate inhibits fructose 1,6-bisphosphatase (FBPase-1), the rate-limiting enzyme of gluconeogenesis, by binding to its active site and preventing catalysis. This inhibition ensures that glycolysis and gluconeogenesis are reciprocally regulated, avoiding futile cycling. In the liver, decreased fructose 2,6-bisphosphate levels during fasting relieve FBPase-1 inhibition, allowing gluconeogenesis to proceed.
Integration with hormonal signaling
In simple terms: Hormones like insulin and glucagon control the levels of fructose 2,6-bisphosphate.
The synthesis and degradation of fructose 2,6-bisphosphate are regulated by hormonal signals. Insulin activates PFKFB kinase activity via phosphorylation, increasing fructose 2,6-bisphosphate and promoting glycolysis. Glucagon, through cAMP-dependent protein kinase A, phosphorylates PFKFB, activating its phosphatase activity and lowering fructose 2,6-bisphosphate, which favors gluconeogenesis. This hormonal control is central to maintaining blood glucose homeostasis.
Key Genes Involved in GO:0006003 fructose 2,6-bisphosphate metabolic process
The following genes encode enzymes and regulators directly involved in fructose 2,6-bisphosphate metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PFKFB1 | Liver and muscle bifunctional enzyme; synthesizes and degrades fructose 2,6-bisphosphate | Hormonal regulation of hepatic glucose metabolism; diabetes research |
| PFKFB2 | Heart bifunctional enzyme; controls cardiac glycolysis | Cardiac ischemia and heart failure models |
| PFKFB3 | Inducible bifunctional enzyme; highly expressed in cancer cells | Warburg effect and tumor growth; oncology targets |
| PFKFB4 | Testis and cancer bifunctional enzyme; regulates glycolysis | Cancer metabolism and proliferation |
| PFKL | Phosphofructokinase-1 liver isoform; activated by fructose 2,6-bisphosphate | Glycolytic flux control; metabolic disorders |
| PFKM | Phosphofructokinase-1 muscle isoform; activated by fructose 2,6-bisphosphate | Muscle glycolysis; exercise physiology |
| PFKP | Phosphofructokinase-1 platelet isoform; activated by fructose 2,6-bisphosphate | Cancer cell glycolysis |
| FBP1 | Fructose 1,6-bisphosphatase; inhibited by fructose 2,6-bisphosphate | Gluconeogenesis and tumor suppression |
| FBP2 | Muscle fructose 1,6-bisphosphatase; inhibited by fructose 2,6-bisphosphate | Muscle metabolism and differentiation |
| GCK | Glucokinase; upstream of fructose 6-phosphate supply | Hepatic glucose sensing; diabetes |
| INSR | Insulin receptor; signals to PFKFB via insulin pathway | Insulin resistance and diabetes |
| GCGR | Glucagon receptor; activates cAMP-PKA to modulate PFKFB | Hepatic gluconeogenesis regulation |
| PRKAA1 | AMPK catalytic subunit; phosphorylates PFKFB3 and affects fructose 2,6-bisphosphate | Energy stress and metabolic reprogramming |
| PRKAA2 | AMPK catalytic subunit; regulates PFKFB2 in heart | Cardiac energy homeostasis |
| AKT1 | Serine/threonine kinase; promotes PFKFB3 expression and glycolysis | Oncogenic signaling and cancer metabolism |
| MYC | Transcription factor; induces PFKFB3 and PFKFB4 expression | Tumor glycolysis and proliferation |
| HIF1A | Hypoxia-inducible factor; upregulates PFKFB3 under hypoxia | Cancer and ischemic adaptation |
| TP53 | Tumor suppressor; regulates glycolysis and fructose 2,6-bisphosphate levels | Cancer metabolism and stress response |
How Is fructose 2,6-bisphosphate metabolic process Regulated?
Fructose 2,6-bisphosphate metabolic process is regulated at multiple levels. Hormonal signals such as insulin and glucagon control the phosphorylation state of PFKFB enzymes, thereby switching between kinase and phosphatase activities. In cancer cells, oncogenes like MYC and HIF1A upregulate PFKFB3 and PFKFB4 expression, increasing fructose 2,6-bisphosphate levels and promoting glycolysis. AMP-activated protein kinase (AMPK) phosphorylates PFKFB3, affecting its activity and stability under energy stress. Additionally, fructose 6-phosphate and citrate allosterically modulate PFKFB kinase activity. This multilayered regulation ensures that fructose 2,6-bisphosphate levels are finely tuned to cellular energy status and hormonal cues.
fructose 2,6-bisphosphate metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PFKFB3 | Cancer (Warburg effect, tumor growth) | Knockout in cancer cell lines (e.g., HeLa, HCT116); xenograft models |
| PFKFB1 | Type 2 diabetes, hyperglycemia | Liver-specific knockout mice; primary hepatocytes |
| PFKFB2 | Cardiac ischemia, heart failure | Cardiomyocyte-specific knockout mice; ischemia-reperfusion models |
| PFKFB4 | Cancer (prostate, breast, glioma) | Knockout in prostate cancer cell lines; orthotopic models |
| FBP1 | Cancer (tumor suppressor), hypoglycemia | Knockout in cancer cells; liver-specific overexpression |
Cancer metabolism
Many cancer cells exhibit elevated glycolysis (the Warburg effect) partly due to increased fructose 2,6-bisphosphate levels. PFKFB3 and PFKFB4 are overexpressed in various tumors and are associated with poor prognosis. Oncogenes such as MYC and HIF1A induce PFKFB3 expression, while loss of tumor suppressors like TP53 can further dysregulate fructose 2,6-bisphosphate metabolism. Targeting PFKFB enzymes is being explored as a therapeutic strategy to selectively starve cancer cells.
Diabetes and metabolic syndrome
In type 2 diabetes, impaired regulation of fructose 2,6-bisphosphate contributes to excessive hepatic glucose production and hyperglycemia. Insulin resistance reduces PFKFB1 kinase activity, lowering fructose 2,6-bisphosphate and favoring gluconeogenesis. Conversely, in some tissues, elevated fructose 2,6-bisphosphate may promote inappropriate glycolysis. Understanding these alterations is key to developing therapies for diabetes and obesity.
Cardiac ischemia and heart failure
The heart relies on fructose 2,6-bisphosphate to stimulate glycolysis during increased workload and ischemia. PFKFB2 is the predominant cardiac isoform, and its activity is regulated by AMPK and insulin signaling. During ischemia, fructose 2,6-bisphosphate levels decline, limiting glycolytic ATP production and contributing to contractile dysfunction. Modulating PFKFB2 activity is a potential approach to protect the ischemic heart.
From fructose 2,6-bisphosphate metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PFKFB3 knockout reduce glycolytic flux and tumor growth? | CRISPR knockout in cancer cell lines and xenografts |
| How does a specific PFKFB1 phosphorylation site affect fructose 2,6-bisphosphate levels? | Point mutation knock-in in hepatocytes or mice |
| Can PFKFB2 overexpression protect the heart from ischemia? | Knock-in of constitutively active PFKFB2 in cardiomyocytes |
| What is the role of PFKFB4 in cancer stem cell maintenance? | CRISPR knockout and overexpression in stem-like cancer cells |
| How does fructose 2,6-bisphosphate regulate global gene expression? | RNA-seq after PFKFB knockout or overexpression |
| Can a tagged PFKFB enzyme reveal its subcellular localization? | Tagged knock-in (e.g., GFP) in cell lines |
How to Study the fructose 2,6-bisphosphate metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | Fructose 2,6-bisphosphate concentration | Quantifying metabolite in cell/tissue extracts |
| Mass spectrometry | Fructose 2,6-bisphosphate and related metabolites | Metabolomics profiling |
| Kinase/phosphatase assay | PFKFB enzyme activities | Characterizing isoform kinetics |
| RNA-seq | PFKFB gene expression | Transcriptional regulation studies |
| Western blot | PFKFB protein levels and phosphorylation | Signaling pathway analysis |
| CRISPR knockout screen | Genes affecting fructose 2,6-bisphosphate levels | Identifying novel regulators |
| Seahorse assay | Glycolytic flux (ECAR) | Functional metabolic phenotyping |
| 13C tracing | Carbon flux through glycolysis/gluconeogenesis | Metabolic pathway analysis |
Metabolite quantification
Fructose 2,6-bisphosphate levels can be measured using enzymatic assays or mass spectrometry. These methods quantify the metabolite in cell or tissue extracts and are essential for linking PFKFB activity to metabolic phenotypes.
Enzyme activity assays
The kinase and phosphatase activities of PFKFB enzymes are measured using radiolabeled substrates or coupled enzymatic reactions. These assays determine the kinetic properties and regulation of PFKFB isoforms.
Gene expression analysis
RNA-seq and qPCR are used to measure PFKFB mRNA levels across tissues and conditions. This reveals transcriptional regulation by oncogenes, hypoxia, and hormones.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that modulate fructose 2,6-bisphosphate levels or sensitivity to glycolytic inhibitors. Such screens uncover novel regulators of this pathway.
How CRISPR Can Be Used to Study GO:0006003 fructose 2,6-bisphosphate metabolic process
Knockout
CRISPR knockout of PFKFB genes (e.g., PFKFB3, PFKFB4) eliminates fructose 2,6-bisphosphate synthesis, leading to reduced glycolytic flux and altered metabolic phenotypes. These models are used to study the role of fructose 2,6-bisphosphate in cancer cell proliferation, survival, and tumor growth.
Point Mutation
Point mutations can be introduced into PFKFB genes to mimic or abolish phosphorylation sites, altering the kinase/phosphatase balance. Such models help dissect how specific residues regulate fructose 2,6-bisphosphate levels in response to hormones.
Knock-in
Knock-in of tagged PFKFB (e.g., GFP or FLAG) allows visualization and immunoprecipitation of the enzyme, revealing its subcellular localization and interaction partners. Knock-in of disease-associated mutations can model human metabolic disorders.
Overexpression
Overexpression of PFKFB isoforms (e.g., PFKFB3) increases fructose 2,6-bisphosphate levels and promotes glycolysis. This is used to study the Warburg effect, cardiac glycolysis, and the consequences of metabolic reprogramming.
How EDITGENE Supports fructose 2,6-bisphosphate metabolic process Research
Researchers studying fructose 2,6-bisphosphate metabolic process-related genes often need to determine whether a candidate gene is causally involved in regulating metabolite levels, glycolytic flux, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes in this pathway.
Contact EDITGENE today to design your custom CRISPR model for fructose 2,6-bisphosphate metabolic process research.
Frequently Asked Questions About fructose 2,6-bisphosphate metabolic process
What is fructose 2,6-bisphosphate metabolic process?
It is the set of chemical reactions that synthesize and degrade fructose 2,6-bisphosphate, a key regulator of glycolysis and gluconeogenesis.
What genes are involved in fructose 2,6-bisphosphate metabolic process?
Key genes include PFKFB1, PFKFB2, PFKFB3, PFKFB4, PFKL, PFKM, PFKP, FBP1, and FBP2, which encode enzymes that produce or respond to fructose 2,6-bisphosphate.
How does fructose 2,6-bisphosphate regulate glycolysis?
It activates phosphofructokinase-1 and inhibits fructose 1,6-bisphosphatase, thereby promoting glycolysis and suppressing gluconeogenesis.
What is the role of PFKFB3 in cancer?
PFKFB3 is overexpressed in many cancers and increases fructose 2,6-bisphosphate levels, supporting aerobic glycolysis and tumor growth.
How is fructose 2,6-bisphosphate metabolism regulated by hormones?
Insulin increases fructose 2,6-bisphosphate by activating PFKFB kinase, while glucagon decreases it by activating the phosphatase via cAMP-PKA signaling.
What diseases are associated with fructose 2,6-bisphosphate dysregulation?
Cancer, type 2 diabetes, and cardiac ischemia are linked to altered fructose 2,6-bisphosphate metabolism.
Can CRISPR be used to study fructose 2,6-bisphosphate metabolism?
Yes, CRISPR knockout, knock-in, and overexpression models of PFKFB genes are widely used to dissect the pathway's role in health and disease.
What methods measure fructose 2,6-bisphosphate levels?
Enzymatic assays and mass spectrometry are commonly used to quantify fructose 2,6-bisphosphate in cells and tissues.
Why is fructose 2,6-bisphosphate important in the heart?
It stimulates cardiac glycolysis to meet energy demand, and its dysregulation contributes to ischemic injury.
What is the evolutionary significance of fructose 2,6-bisphosphate metabolism?
It is conserved across eukaryotes, highlighting its fundamental role in metabolic regulation.
Conclusion
Fructose 2,6-bisphosphate metabolic process (GO:0006003) is a central regulatory node that controls the balance between glycolysis and gluconeogenesis. Its dysregulation is implicated in cancer, diabetes, and heart disease, making it a prime target for metabolic research. By leveraging CRISPR-based models and advanced bioinformatics, researchers can uncover new therapeutic opportunities targeting this pathway.
References
- 1. Van Schaftingen E. 1987. Fructose 2,6-bisphosphate.. Adv Enzymol Relat Areas Mol Biol 59:315-95 PMID: 3028056
- 2. Van Schaftingen E. 1993. Glycolysis revisited.. Diabetologia 36(7):581-8 PMID: 8395434
- 3. Michels PA et al.. 2006. Evolutionary analysis of fructose 2,6-bisphosphate metabolism.. IUBMB Life 58(3):133-41 PMID: 16766380
- 4. Okar DA et al.. 1999. Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes.. Biofactors 10(1):1-14 PMID: 10475585
- 5. Pilkis SJ et al.. 1990. Fructose-2,6-bisphosphate in control of hepatic gluconeogenesis. From metabolites to molecular genetics.. Diabetes Care 13(6):582-99 PMID: 2162755
- 6. Hers HG. 1983. Fructose 2,6-bisphosphate.. Biochem Soc Trans 11(3):250-1 PMID: 6307768
- 7. Hue L et al.. 1993. Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.. Adv Enzyme Regul 33:97-110 PMID: 8395137
- 8. Depre C et al.. 1993. Role of fructose 2,6-bisphosphate in the control of heart glycolysis.. J Biol Chem 268(18):13274-9 PMID: 8514765
